These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17132752)

  • 1. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly.
    Hua SC; Yan YH; Chang TC
    Eur J Endocrinol; 2006 Dec; 155(6):831-7. PubMed ID: 17132752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
    Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
    Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.
    Bolanowski M; Hubalewska-Dydejczyk A; Kos-Kudła B; Ruchała M; Witek P; Zgliczyński W; Houchard A; Bartmańska M
    Endokrynol Pol; 2021; 72(5):512-519. PubMed ID: 34647602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
    Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
    Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options.
    Felt JM; Depaoli SA; Pereira AM; Biermasz NR; Tiemensma J
    Eur J Endocrinol; 2015 Jul; 173(1):37-42. PubMed ID: 25872514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire.
    Vandeva S; Yaneva M; Natchev E; Elenkova A; Kalinov K; Zacharieva S
    Endocrine; 2015 Aug; 49(3):774-82. PubMed ID: 25561370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL).
    Trepp R; Everts R; Stettler C; Fischli S; Allemann S; Webb SM; Christ ER
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):103-10. PubMed ID: 15963069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acromegaly improves quality of life, measured by AcroQol.
    Paisley AN; Rowles SV; Roberts ME; Webb SM; Badia X; Prieto L; Shalet SM; Trainer PJ
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):358-62. PubMed ID: 17555502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly.
    T'Sjoen G; Bex M; Maiter D; Velkeniers B; Abs R
    Eur J Endocrinol; 2007 Oct; 157(4):411-7. PubMed ID: 17893254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.
    Webb SM; Badia X; Surinach NL;
    Eur J Endocrinol; 2006 Aug; 155(2):269-77. PubMed ID: 16868140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life.
    Andela CD; Biermasz NR; Kaptein AA; Pereira AM; Tiemensma J
    Growth Horm IGF Res; 2015 Oct; 25(5):219-26. PubMed ID: 26164770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study.
    Kyriakakis N; Lynch J; Gilbey SG; Webb SM; Murray RD
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):806-815. PubMed ID: 28316090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.
    Yoshida K; Fukuoka H; Matsumoto R; Bando H; Suda K; Nishizawa H; Iguchi G; Ogawa W; Webb SM; Takahashi Y
    Pituitary; 2015 Dec; 18(6):876-83. PubMed ID: 26123761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.
    Rowles SV; Prieto L; Badia X; Shalet SM; Webb SM; Trainer PJ
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3337-41. PubMed ID: 15755865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study.
    Sardella C; Lombardi M; Rossi G; Cosci C; Brogioni S; Scattina I; Webb SM; Gasperi M; Martino E; Bogazzi F
    J Endocrinol Invest; 2010 Jan; 33(1):20-5. PubMed ID: 20203538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.
    Postma MR; Netea-Maier RT; van den Berg G; Homan J; Sluiter WJ; Wagenmakers MA; van den Bergh AC; Wolffenbuttel BH; Hermus AR; van Beek AP
    Eur J Endocrinol; 2012 Apr; 166(4):585-92. PubMed ID: 22250074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.